NDA 219042 · Boehringer Ingelheim
Hernexeos
Zongertinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewCDER novel approval, Aug 8, 2025: To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Aug 8, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
20
2 Phase 3, 6 recruiting
FAERS reports
167
120 serious, 23 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 13, 2026.
HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ] . This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. HERNEXEOS is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. ( 1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 )
Mechanism: Zongertinib is a kinase inhibitor of human epidermal growth factor receptor 2 (HER2). In vitro, zongertinib inhibited phosphorylation of HER2, downstream signaling of HER2 (phosphorylation of ERK), and proliferation of lung cancer cells harboring HER2 tyrosine kinase domain activating mutations. In vivo, zongertinib demonstrated anti-tumor activity in mouse xenograft models of NSCLC harboring HER2 tyrosine kinase domain activating mutations.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 26, 2026 Supplement 1 · Efficacy · priority review Breakthrough therapyLabelLetter
- Aug 8, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
1 products under this application
- HERNEXEOS · ZONGERTINIB 60MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zongertinib" as an intervention, any sponsor and status, largest first.
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06324357 · 910 participants (planned) · Start Jun 28, 2024 · Primary completion Jan 8, 2029
Drug: Zongertinib; Trastuzumab deruxtecan and 6 more · For: Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma and 2 more
Sites: Cerritos, California; Los Angeles, California; Orange, California · 105 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT06581432 · 588 participants (planned) · Start Oct 11, 2024 · Primary completion Nov 30, 2028
Drug: Zongertinib · For: Solid Tumours
Sites: Anchorage, Alaska; Tucson, Arizona; Beverly Hills, California · 93 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT04886804 · 554 participants (planned) · Start Jul 2, 2021 · Primary completion Feb 29, 2028
Drug: zongertinib · For: Neoplasm Metastasis; Non-Small Cell Lung Cancer
Sites: Birmingham, Alabama; Beverly Hills, California; Duarte, California · 85 sites in all
- Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentPivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06151574 · 428 participants · Start Feb 9, 2024 · Primary completion Dec 10, 2026
Drug: zongertinib; pembrolizumab and 3 more · For: Lung Cancer, Non-squamous, Non-small Cell
Sites: Huntsville, Alabama; Bullhead City, Arizona; Beverly Hills, California · 163 sites in all
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07195695 · 400 participants (planned) · Start Jan 16, 2026 · Primary completion Feb 26, 2032
Drug: Zongertinib; Pembrolizumab and 3 more · For: Non-small Cell Lung Cancer
Sites: Fresno, California; Glendale, California; Orange, California · 205 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT07486817 · 60 participants (planned) · Start Jun 4, 2026 · Primary completion Aug 12, 2027
Drug: Zongertinib; Cisplatin and 3 more · For: Lung Cancer, Non-squamous, Non-small Cell
Sites: St Leonards, Australia; Malvern, Australia; Murdoch, Australia · 20 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT07789028 · 56 participants (planned) · Start Sep 9, 2026 · Primary completion Dec 15, 2026
Drug: Zongertinib, Formulation A, reference product; Zongertinib Formulation B, test product · For: Healthy
Sites: Biberach, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT06360081 · 56 participants · Start Apr 30, 2024 · Primary completion Jun 30, 2024
Drug: Zongertinib manufacturer 1; Zongertinib manufacturer 2 · For: Healthy
Sites: Mannheim, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea45
- disease progression25
- malignant neoplasm progression21
- metastases to central nervous system13
- rash11
- nausea10
- hepatic function abnormal9
- death8
- decreased appetite8
- dyspnoea5
- pleural effusion5
- blood creatinine increased4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 21 |
| 2026 | 144 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
Heymach JV, Ruiter G, Ahn MJ, et al. · N Engl J Med 2025 · Clinical Trial, Phase I, Multicenter Study
- First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Heymach JV, Yamamoto N, Girard N, et al. · N Engl J Med 2026 · Clinical Trial, Phase I, Multicenter Study
- HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.
Heymach JV, Opdam F, Barve M, et al. · J Clin Oncol 2025 · Clinical Trial, Phase I, Multicenter Study
- Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH.
Wölke S, Sadrolhefazi B, Esmaeili H, et al. · Mol Pharm 2025 · Randomized Controlled Trial
- Absorption, Metabolism, Distribution and Excretion (ADME) and Absolute Bioavailability Assessment of Zongertinib in Healthy Male Volunteers.
Grempler R, Joseph D, Gan G, et al. · Clin Drug Investig 2026 · Clinical Trial, Phase I
- Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies.
Pereira H, Wölke S, Sadrolhefazi B, et al. · Mol Pharm 2025 · Randomized Controlled Trial, Clinical Trial, Phase I
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.